In 2002, the *cell cycle checkpoint kinase 2* (*CHEK2*) gene was identified as the first moderate-risk susceptibility gene for breast cancer. The *CHEK2* 1100delC mutation has been associated with a two- to three-fold increased risk of developing breast cancer in women ([@bib16]; [@bib29]; [@bib33]; [@bib6]). The frequency of the *CHEK2* 1100delC mutation is relatively high in the Netherlands, being ∼1% in the general population, 2--4% in unselected breast cancer patients and 5--6% in breast cancer patients with a family history of breast cancer ([@bib29]; [@bib28]; [@bib11]).

The CHEK2 kinase acts as a tumour suppressor and plays a critical role in DNA damage repair. Because of a compromised DNA repair mechanism, it has been hypothesised that *CHEK2* mutation carriers might have an increased sensitivity to chemotherapeutic agents causing double-strand DNA breaks, such as platinum or anthracyclines ([@bib20]).

Previous studies showed that *CHEK2* 1100delC-associated breast cancer patients had mainly oestrogen receptor (ER)-positive tumours ([@bib7]; [@bib19]; [@bib34]), and a higher incidence of contralateral breast cancer compared with noncarriers ([@bib8]; [@bib26]; [@bib34]). In addition, a worse disease-free and overall survival has been observed in *CHEK2* 1100delC-associated breast cancer patients compared with patients without this mutation ([@bib8]; [@bib26]; [@bib34]). In the overall breast cancer population, the risk of contralateral breast cancer is reduced by adjuvant chemotherapy ([@bib2]; [@bib22]). Data on the impact of adjuvant chemotherapy on the contralateral breast cancer risk and survival of *CHEK2* 1100delC-associated breast cancer patients *vs* noncarriers have not been reported yet. If *CHEK2* 1100delC mutation carriers are indeed more sensitive to chemotherapy due to a defective DNA repair mechanism, the differences in contralateral breast cancer incidence and in distant disease-free and breast cancer-specific survival in *CHEK2* mutation carriers compared with noncarriers would be most pronounced in breast cancer patients not treated with adjuvant chemotherapy.

In this study we therefore evaluated the contralateral breast cancer rate, distant disease-free survival and breast cancer-specific survival in breast cancer patients with the *CHEK2* 1100delC mutation compared with patients without this mutation, stratified for adjuvant treatment with chemotherapy.

Materials and Methods
=====================

Three different cohorts of women with invasive early breast cancer were included in this study. Overall inclusion criteria were: age at diagnosis of first breast cancer \<80 years, diagnosis of first breast cancer after 1970, no distant metastases at or within 3 months after primary diagnosis, no proven *BRCA1* or *BRCA2* mutation and follow-up data available.

The first cohort (*n*=1220) consisted of breast cancer patients ascertained through the Rotterdam Family Cancer Clinic. All selected patients were tested negative for *BRCA1* and *BRCA2* mutations. We refer to this cohort as the 'non-*BRCA1/2*\' cohort.

The second cohort (*n*=1014, after exclusion of 64 patients already included in the non-*BRCA1/2* cohort) consisted of patients enrolled in the ORIGO study, designed to investigate the percentage of *BRCA1/2* mutations in an unselected breast cancer population. This study concerned a consecutive series of breast cancer patients. Data on contralateral breast cancer rate and survival for *CHEK2* mutation carriers *vs* non-carriers have been previously described ([@bib8]). We refer to this cohort as 'ORIGO\'.

The third cohort was drawn from the Rotterdam Medical Oncology Tumour bank (RMOT) database (*n*=2488, after exclusion of 114 patients already included in the non-*BRCA1/2* cohort and 1 patient already included in the ORIGO cohort). The RMOT database included breast cancer patients mainly diagnosed in the South Western region of the Netherlands from whom fresh frozen breast tumour specimens were submitted to the Erasmus MC for routine ER and progesterone receptor (PgR) measurement between 1978 and 2004. We refer to this cohort as 'RMOT\'.

Part of the non-*BRCA1/2* cohort (57%) and the entire ORIGO cohort were also included in the study of [@bib34]), investigating survival and contralateral breast cancer risk in *CHEK2* 1100delC mutation carriers. For the current study, follow-up of the patients in both cohorts has been updated to July 2010.

For all eligible patients of the three cohorts, data on patient and tumour characteristics, treatment and follow-up were collected from the medical records. The study was approved by the Institutional Review Board.

Genotyping
----------

DNA was isolated from peripheral blood for patients from the non-*BRCA1/2* and ORIGO cohorts and from freshly frozen tumour tissue for patients from the RMOT cohort ([@bib28]; [@bib23]). The *CHEK2* 1100delC mutation status was determined by either allele-specific oligonucleotide hybridisation or Taqman genotyping as described earlier ([@bib16]; [@bib12]). A number of samples (*n*=783) were analysed with both methods, showing a concordance of 100% between the two methods.

Statistical analyses
--------------------

Differences in patient and tumour characteristics and types of treatment between *CHEK2* 1100delC mutation carriers and noncarriers were compared by *t*-test (continuous variables) or *χ*^2^ test (categorical variables). Events of interest were metachronous contralateral breast cancer (diagnosed \>3 months after diagnosis of the first breast cancer), distant metastases and breast cancer-specific death. For analyses regarding metachronous contralateral breast cancer, the non-*BRCA1/2* cohort was excluded, because this cohort probably is enriched with cases with bilateral breast cancer cases as contralateral breast cancer is one of the criteria for referral for genetic testing for *BRCA1/2* mutations and therefore might overestimate the contralateral breast cancer incidence. Kaplan--Meier curves were constructed for contralateral breast cancer rate, distant disease-free survival and breast cancer-specific survival for *CHEK2* 1100delC mutation carriers and noncarriers separately. Censoring events overall were death not related to breast cancer, last medical contact or end of this study (1 July 2010), and for contralateral breast cancer rate it also included death because of breast cancer and preventive bilateral or contralateral mastectomy. Differences in outcome between *CHEK2* 1100delC mutation carriers and noncarriers were tested by the log rank test.

We calculated univariate and multivariate hazard ratios (HRs) and 95% confidence intervals (CIs) for the above-mentioned events for mutation carriers *vs* noncarriers by the Cox proportional hazard method. Models were adjusted for patient, tumour and treatment factors, including age at and year of diagnosis, cohort (non-*BRCA1/2*, ORIGO, RMOT), tumour size (T1, T2, T3 or T4, unknown), nodal status (negative, positive, unknown), hormone receptor status (negative, positive, unknown), differentiation grade (1, 2, 3, unknown), type of surgery (lumpectomy, mastectomy, none or unknown), adjuvant chemotherapy (yes, no, unknown), adjuvant hormonal therapy (yes, no, unknown) and radiotherapy (yes, no, unknown), and the models for distant disease-free and breast cancer-specific survival also for contralateral breast cancer as time-dependent variable. Tumour ER and PgR analyses were performed by ligand binding assay or enzyme-linked immunoassay. The cutoff for ER and PgR positivity was 10 fmol mg^−1^ cytosolic protein or ⩾10% immunopositive cells. A negative hormone receptor status was defined as negativity for both ER and PgR, and a positive hormone receptor status as positivity for ER and/or PgR. Hormone receptor status was considered as unknown if information on both ER and PgR status was lacking, or in case of negative ER and unknown PgR status.

The proportional hazard assumption was assessed by using an extended Cox model with time-depending covariables. A likelihood ratio test was used to test whether an extended model was significantly different compared with the proportional hazard model. The extended models for *CHEK2* and tumour size were significant for both distant metastases (*P*=0.003 and *P*=0.002, respectively) and breast cancer-specific death (*P*=0.02 and *P*=0.04), indicating that the hazards for distant metastases and breast cancer-specific death by *CHEK2* 1100delC and tumour size were not proportional over time. Because the survival curves for distant disease-free and breast cancer-specific survival for *CHEK2* mutation carriers and noncarriers were similar over the first 6 years, but started to diverge after 6 years (Figure 2A and D), we chose for an extended Cox model with tumour size as time-dependent variable and that contains a heaviside function ([@bib14]), together with the *CHEK2* 1100delC variable, with a cutoff point of 6 years. The corresponding model then provided two hazard ratios for *CHEK2* 1100delC, one for the first 6 years and one for beyond 6 years after breast cancer diagnosis.

Analyses for contralateral breast cancer distant disease-free and breast cancer-specific survival were stratified for adjuvant treatment with chemotherapy (yes/no). Analyses for distant disease-free survival were also stratified for type of adjuvant chemotherapy (anthracycline-based/nonanthracycline-based) and adjuvant hormonal therapy (yes/no).

Interaction terms between *CHEK2* 1100delC mutation status and administration of adjuvant chemotherapy (yes/no) for the different end points were calculated. In addition, the prognostic impact of age at diagnosis, tumour size, nodal status, ER status, chemotherapy and hormonal therapy were analysed separately for *CHEK2* 1100delC and non-*CHEK2* patients.

All analyses were performed using SPSS (version 20.0; SPSS, Inc., Chigago, IL, USA) and Stata (version 12; Stat Corporation, College Station, TX, USA). A two-sided *P*\<0.05 was considered as statistically significant.

Results
=======

In total, 193 (4.1%) of the 4722 included female breast cancer patients tested positive for the *CHEK2* 1100delC mutation ([Table 1](#tbl1){ref-type="table"}). The percentage of *CHEK2* 1100delC mutations was highest in the non-*BRCA1/2* cohort (6.3%, *n*=77) *vs* 2.9% (*n*=29) in the ORIGO and 3.5% (*n*=87) in the RMOT cohort, respectively.

Patient and tumour characteristics of the 193 *CHEK2* 1100delC mutation carriers and the 4529 non-carriers are shown in [Table 2](#tbl2){ref-type="table"}. The median follow-up time was 6.8 years for mutation carriers and 7.2 years for noncarriers. The *CHEK2* 1100delC-associated breast cancer patients were significantly younger at diagnosis than the noncarriers (median 50.0 *vs* 51.4 years). In addition, mutation carriers were more often diagnosed with breast cancer after 2000 (26.9% *vs* 20.8%), probably reflecting the higher percentage of *CHEK2* 1100delC mutation carriers in the non-*BRCA1/2* cohort, as patients in this cohort were more often diagnosed after 2000 (51%) compared with patients from the RMOT cohort (\<1%) and ORIGO cohort (37% data not shown in tables). Breast cancers in mutation carriers were more often hormone receptor positive compared with cancers in noncarriers (94.5% *vs* 80.7%). No significant differences in tumour size, nodal status, differentiation grade and her2 expression were observed between *CHEK2* 1100delC mutation carriers and noncarriers.

Types of treatment are shown in [Table 3](#tbl3){ref-type="table"}. Significantly less *CHEK2*-associated breast cancer patients received radiotherapy compared with the noncarriers (62.0% *vs* 71.3%). This observation could not be explained by differences in surgical therapy (lumpectomy *vs* mastectomy), TN stage or age at diagnosis, but might be partly explained by differences in the year of diagnosis between the two groups (see [Table 2](#tbl2){ref-type="table"}). Adjuvant chemotherapy was administered to 31% of the patients, mainly consisting of anthracycline-containing regimens, and 24% of the patients received adjuvant endocrine therapy, mainly consisting of tamoxifen. This was not significant different between *CHEK2* mutation carriers and noncarriers.

Contralateral breast cancer risk
--------------------------------

The incidence of metachronous contralateral breast cancer was higher in *CHEK2* 1100delC mutation carriers than in noncarriers, with a 10-year risk of 28.9% *vs* 8.5%, respectively ([Table 4](#tbl4){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). In a multivariate analysis, the risk of contralateral breast cancer remained higher in mutation carriers compared with noncarriers (HR 3.97, 95% CI 2.59--6.07).

If stratified for adjuvant chemotherapy, the increased contralateral breast cancer rate for *CHEK2* 1100delC-associated breast cancer patients was observed in both the group treated with and without chemotherapy (HR multivariate 6.95, 95% CI 3.21--15.00 and 3.15, 95% CI 1.86--5.35, respectively). Although the HR was higher for patients treated with adjuvant chemotherapy, no significant interaction between the *CHEK2* 1100delC mutation and adjuvant chemotherapy was observed (HR for interaction 2.15; *P*=0.10; not shown in Tables). Stratifying for adjuvant endocrine therapy was not possible because only 19 *CHEK2* 1100delC-associated breast cancer patients were treated with hormonal therapy. No contralateral breast cancers were observed in these 19 patients.

Survival
--------

The data regarding distant disease-free survival are shown in [Table 5](#tbl5){ref-type="table"} and [Figure 2A--C](#fig2){ref-type="fig"} and regarding breast cancer-specific survival in [Table 5](#tbl5){ref-type="table"} and [Figure 2D--F](#fig2){ref-type="fig"}. The Kaplan--Meier curves showed a nonsignificant decreased distant disease-free (*P*=0.06) and breast cancer-specific survival (*P*=0.14) for *CHEK2*-associated patients compared with non-*CHEK2* patients ([Figure 2A and D](#fig2){ref-type="fig"}).

As can be observed in the Kaplan--Meier curves, the distant disease-free ([Figure 2A](#fig2){ref-type="fig"}) and breast cancer-specific survival ([Figure 2D](#fig2){ref-type="fig"}) were similar over the first 6 years after breast cancer diagnosis for *CHEK2* 1100delC mutation carriers and noncarriers and started to diverge after 6 years. In the first 6 years after breast cancer diagnosis, the multivariate hazard ratios for *CHEK2 vs* non-*CHEK2* breast cancer patients were not significant for distant disease-free (1.08; 95% CI 0.83--1.42) and breast cancer-specific survival (1.00, 95% CI 0.71--1.41). Survival outcomes beyond 6 years after breast cancer diagnosis, however, were significantly worse for *CHEK2* mutation carriers compared with noncarriers. Multivariate HRs for the period beyond 6 years after breast cancer diagnosis were 2.65 (95% CI 1.79--3.93) for distant disease-free and 2.05 (95% CI 1.41--2.99) for breast cancer-specific survival, respectively.

If we stratified our analyses for adjuvant chemotherapy, a significantly worse distant disease-free (*P*=0.002) and a trend for a worse breast cancer-specific survival (*P*=0.05) were observed for *CHEK2*-associated compared with non-*CHEK2-*associated breast cancer patients in the chemotherapy group ([Figure 2C and F](#fig2){ref-type="fig"}) that was not observed in the group not treated with chemotherapy (*P*=0.52 and *P*=0.40, respectively, [Figure 2B and E](#fig2){ref-type="fig"}). However, in both treatment groups, the group treated with and the group treated without adjuvant chemotherapy, we observed in the first 6 years after breast cancer diagnosis no significant differences in distant disease-free survival between *CHEK2* mutation carries and noncarriers (HR multivariate 1.41, 95% CI 0.91--2.16 and HR multivariate 0.98, 95% CI 0.69--1.38, respectively; [Table 5](#tbl5){ref-type="table"}), whereas beyond 6 years after breast cancer diagnosis, a significantly worse distant disease-free survival in *CHEK2* mutation carriers compared with noncarriers was observed for both the adjuvant chemotherapy group (HR 4.54, 95% CI 2.41--8.65) and the group without adjuvant chemotherapy (2.31, 95% CI 1.39--3.83). Although the HRs were higher in the adjuvant chemotherapy group compared with the group without adjuvant chemotherapy, no significant interaction was observed between *CHEK2* 1100delC and adjuvant chemotherapy (HR interaction 1.51; *P*=0.08; data not shown in tables).

If analysing patients treated with anthracycline-based chemotherapy and nonanthracycline-based chemotherapy separately, we observed in both groups a significantly worse distant disease-free survival beyond 6 years after breast cancer diagnosis for *CHEK2* mutation carriers compared with noncarriers (HR multivariate 4.16, 95% CI 1.69--10.22 and 4.73 95% CI 1.85--12.09, respectively; [Table 5](#tbl5){ref-type="table"}).

In addition, stratifying for treatment with hormonal therapy (yes/no) had no major impact on the hazard ratio for disease-free survival. The *CHEK2*-associated breast cancer patients had a significantly worse distant disease-free survival than noncarriers beyond 6 years after diagnosis, independently of treatment with adjuvant hormonal therapy (HR 3.24, 95% CI 1.16--9.03) or without adjuvant hormonal therapy (HR 2.88, 95% CI 1.88--4.41; [Table 5](#tbl5){ref-type="table"}).

For breast cancer-specific survival a similar phenomenon was observed; only beyond 6 years after breast cancer diagnosis a significantly worse breast cancer-specific survival was observed for *CHEK2* mutation carriers *vs* noncarriers in both adjuvant chemotherapy groups (i.e., the group treated with and without adjuvant chemotherapy). In the first 6 years after breast cancer diagnosis, we observed no significant difference in breast cancer-specific survival between *CHEK2* mutation carriers and noncarriers ([Figure 2D--F](#fig2){ref-type="fig"} and [Table 5](#tbl5){ref-type="table"}).

In [Table 6](#tbl6){ref-type="table"}, multivariate HRs with respect to breast cancer-specific survival are presented for several prognostic factors, separately for *CHEK2* and non-*CHEK2* patients. Age at diagnosis, tumour size and nodal status appeared to be prognostic factors in both groups, although the prognostic value of age at diagnosis was not significant in the *CHEK2* group. Interestingly, ER status appeared only to be a prognostic factor in the non-*CHEK2* group (HR 0.58, 95% CI 0.45--0.75) and not in the *CHEK2* group (HR 1.11, 95% CI 0.43--2.84). Administration of adjuvant chemotherapy (HR 0.70 95% CI 0.35--1.41) and of adjuvant hormonal therapy (HR 0.62, 95% CI 0.30--1.28) had a nonsignificant favourable effect on breast cancer-specific survival in the *CHEK2* group.

Discussion
==========

In this study, we observed a worse distant disease-free and breast cancer-specific survival for *CHEK2* 1100delC-associated compared with noncarrier patients, becoming apparent beyond 6 years after breast cancer diagnosis. Furthermore, we confirmed the higher incidence of contralateral breast cancer in breast cancer patients carrying the *CHEK2* 1100delC mutation, as observed in earlier studies ([@bib8]; [@bib26]; [@bib34]). Both observations were not influenced by chemotherapy, suggesting no differential efficacy of chemotherapy in *CHEK2* 1100delC mutation carriers.

Interestingly, the worse distant disease-free and breast cancer-specific survival in *CHEK2* 1100delC mutation carriers was only observed beyond 6 years after breast cancer diagnosis, rather than immediately after breast cancer diagnosis. Although earlier studies also observed or suggested a worse (distant disease-free) survival in *CHEK2* 1100delC mutation carriers ([@bib8]; [@bib26]; [@bib34]), none of these studies showed the phenomenon that we observed. In view of these discordant results, we further performed analyses in the three patient cohorts, and found that the trend for a worse distant disease-free and breast cancer-specific survival beyond 6 years was only observed in the RMOT cohort, whereas in the other two cohorts the survival became worse as of diagnosis (significant for the ORIGO cohort and nonsignificant for the non-*BRCA1/2* cohort; data not shown). A reason for this different observation in the RMOT compared with the non-*BRCA1/2* and ORIGO cohorts might be different patient characteristics in the RMOT cohort, such as the higher age at diagnosis (median 55 years compared with 44 and 52 years, respectively) and earlier diagnose years, resulting in a lower percentage of patients treated with adjuvant chemotherapy (19% *vs* 52% and 37%, respectively) and adjuvant hormonal therapy (14% *vs* 36% and 35%, respectively) and other types of treatment (more often CMF and less often anthracycline-based or taxane-based regimens). As adjuvant hormonal therapy is generally given for a period of 5 years, it can be hypothesised that the worse survival beyond 6 years in *CHEK2-*associated breast cancer patients might be an effect of the hormonal therapy. However, evidence for this hypothesis is not found in this study as we observed in both groups (i.e., the group treated with and the group treated without adjuvant hormonal therapy) a worse survival in *CHEK2* mutation carriers compared with noncarriers more than 6 years after breast cancer diagnosis. It can also be hypothesised that the worse distant disease-free and breast cancer-specific survival for *CHEK2* mutation carriers after 6 years is caused by the higher incidence of contralateral breast cancer in this group. However, this worse distant disease-free and breast cancer-specific survival remained if we censored at time of metachronous contralateral breast cancer and/or local recurrences (data not shown) and if we included contralateral breast cancer as time-dependent covariable in the extended Cox models, indicating that the observed worse survival measures are not only due to the higher incidence of contralateral breast cancer and/or local recurrences in the *CHEK2* group. As the worse distant disease-free and breast cancer-specific survival cannot be explained by a reduced sensitivity to systemic therapy and by the higher incidence of contralateral breast cancer, we suppose that a different tumour biology might play a role. More research is needed into tumour biology of *CHEK2* breast cancers.

The CHEK2 kinase acts as a tumour suppressor and plays a critical role in DNA damage repair. In response to double-strand DNA breaks, CHEK2 is activated by ataxia telangiectasia mutated (ATM) and involved in cell cycle control, DNA repair and apoptosis. The CHEK2 kinase phosphorylates TP53 and BRCA1, whereupon BRCA1 represses the nonhomologous end-joining pathway and activates the homologous recombination repair pathway ([@bib20]; [@bib31]; [@bib25]). Based on the role of CHEK2 kinase in activating the repair mechanism of double-strand DNA breaks and the role of CHEK2 in the coordination of the mitotic spindle assembly, we hypothesised that *CHEK2* 1100delC mutation carriers might be more sensitive to chemotherapy. For *BRCA1-*associated breast cancer patients, there is growing evidence from *in vitro* studies on BRCA1-deficient cells and retrospective clinical studies on *BRCA1* mutation carriers suggesting a higher sensitivity to chemotherapeutic agents causing double-strand DNA breaks, such as platinum or anthracyclines ([@bib15]; [@bib1]). However, the results found in the current study do not support the hypothesis that *CHEK2* mutation carriers have an increased sensitivity to chemotherapy, neither for anthracycline-based regimens nor for nonanthracycline-based regimens. In contrast, the observations on the worse distant disease-free and breast cancer-specific survival and the higher contralateral breast cancer rate in *CHEK2* mutation carriers being most pronounced in the group treated with chemotherapy suggest that *CHEK2* mutation carriers are rather less than more sensitive to chemotherapy compared with noncarrier breast cancer patients. However, as the interaction between *CHEK2* and adjuvant chemotherapy is not significant, we cannot prove a decreased sensitivity to adjuvant chemotherapy in *CHEK2* breast cancer patients. It might be that differences in patient and tumour characteristics between the groups treated with and without adjuvant chemotherapy may have influenced the results of the analyses stratified for adjuvant chemotherapy. Patients treated with adjuvant chemotherapy were younger at diagnosis, were more often diagnosed after 2000 (anthracycline-based chemotherapy being common), had a larger tumour size, had more often node positive and hormone receptor negative tumours and were more often treated with mastectomy and hormonal therapy than patients not treated with adjuvant chemotherapy. It might be that especially younger or node-positive *CHEK2*-associated breast cancer patients have a worse prognosis compared with noncarriers.

The increased risk of contralateral breast cancer in *CHEK2* 1100delC mutation carriers was observed in patients treated with adjuvant chemotherapy as well as in patients not receiving adjuvant chemotherapy. A factor to take into account hereby is radiotherapy, as it was suggested that *CHEK2* mutation carriers might be more sensitive to ionising radiation ([@bib5], [@bib4]; [@bib17]). However, in multivariate analyses we found an increased risk of contralateral breast cancer in both patients treated with (HR 4.12 95% CI 2.49--6.83) and without radiotherapy (HR 3.17 95% CI 1.36--7.35; data not shown).

The strengths of our study include the relatively large sample size, the known tumour and treatment data and the homogeneous population from one country. To our knowledge, this is in fact the largest study on survival in *CHEK2* 1100delC breast cancer patients with available treatment data enabling to investigate the effect of adjuvant chemotherapy in this data set.

We are however aware of some limitations. First, this is a retrospective study and consequently treatment was provided on indication, according to the Dutch guidelines existing for the respectively treatment years. Although treatment guidelines have changed over time, in general, patients with the worst prognosis (based on age at diagnosis and tumour stage/characteristics) received adjuvant chemotherapy. This probably is the reason why patients receiving adjuvant chemotherapy had a worse distant disease-free survival (median 6.5 and 15.0 years for *CHEK2* mutation carriers and noncarriers, respectively; [Figure 2C](#fig2){ref-type="fig"}) compared with patients not receiving adjuvant chemotherapy (11.0 and 16.8 years for mutation carriers and noncarriers, respectively; [Figure 2B](#fig2){ref-type="fig"}).

Another possible limitation is longevity bias in the non-*BRCA1/2* group, developed by selection of preferably long-living patients who were tested for *BRCA1/2* mutations (long) after their breast cancer diagnosis. After stratifying for cohort, we indeed observed the longest survival within the non-*BRCA1/2* cohort. However, we also performed left-truncated analyses, and the results were similar as those from the initial analyses, with a worse distant disease-free and breast cancer-specific survival beyond 6 years after diagnosis for *CHEK2* mutation carriers compared with noncarriers (data not shown).

Finally, genetic testing for *CHEK2* 1100delC within the RMOT cohort was performed on DNA isolated from tumour tissue and not from peripheral blood. It is possible that some germline *CHEK2* 1100delC mutations were missed because the mutant *CHEK2* allele was lost in the tumour instead of the wild-type allele ([@bib27]; [@bib13]). Moreover, a detected *CHEK2* 1100delC mutation in the tumour might have been acquired somatically, being different from a germline mutation. Importantly, there were no discrepancies in DNA analyses test results of *CHEK2* status observed when comparing blood and tumour sample test of 115 patients.

Currently, genotyping for *CHEK2* is not yet performed at genetic testing for breast cancer as it is not considered to have clinical consequences. Moreover, implementation of *CHEK2* genotyping (and especially presymptomatic testing of relatives) is complicated by the observation that in breast cancer families the breast cancer risk does not segregate completely with the presence or absence of the 1100delC mutation ([@bib28]). However, the high incidence of contralateral breast cancer in *CHEK2* 1100delC mutation carriers found in the current study (10-year risk 24.1%) and in earlier studies is comparable to the incidence of contralateral breast cancer that we observed in *BRCA1* and *BRCA2* mutation carriers in an earlier study (10-year risk 25% and 20%, respectively) ([@bib3]) and in line with observations of other groups (10-year risk ranging between 13 and 37%) ([@bib10]; [@bib18]; [@bib24]; [@bib21]; [@bib9]; [@bib32]). Based on this increased contralateral breast cancer rate, affected *BRCA1/2* mutation carriers have a more intensive follow-up scheme for contralateral breast cancer detection including MRI or can opt for a risk-reducing contralateral mastectomy, even though it is unknown whether such a risk-reducing contralateral mastectomy can improve survival ([@bib30]). In our opinion, this follow-up regimen should also be offered to *CHEK2* 1100delC mutation carriers after breast cancer diagnosis. In addition, as the population frequency of the *CHEK2* 1100delC mutation in the Netherlands is high, it may be relevant to discuss the implementation of genotyping for *CHEK2* in breast cancer patients. Moreover, genetic testing for *CHEK2* 1100delC and may be other variants may also be considered in other populations where the mutation frequency is relevantly high such as Finland, Sweden, United Kingdom and North America ([@bib11]).

In conclusion, *CHEK2* 1100delC mutation carriers had a significantly higher incidence of contralateral breast cancer compared with noncarriers that may have consequences for follow-up strategies in clinical practice. Distant disease-free and breast cancer-specific survival were similar over the first 6 years after diagnosis, but became worse beyond 6 years after diagnosis for *CHEK2* 1100delC mutation carriers compared with noncarrier BC patients. No significant interaction between adjuvant chemotherapy and a *CHEK2* 1100delC mutation was observed regarding contralateral breast cancer or distant disease-free survival.
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![**Contralateral breast cancer rate for *CHEK2-*positive (green line) and *CHEK2-*negative patients (blue line) in (**A**) all patients, (**B**) patients not treated with systemic therapy and (**C**) patients treated with systemic therapy.** \*Patients with synchronous contralateral breast cancer and patients from the non-BRCA1/2 cohort were excluded for this analysis regarding metachronous contralateral breast cancer. ^\#^In (**B** and **C**), stratified for adjuvant chemotherapy, one additional carrier and four noncarriers for whom treatment with adjuvant chemotherapy was unknown were excluded. The full colour version of this figure is available at *British Journal of Cancer* online.](bjc2014306f1){#fig1}

![**Distant disease-free survival for *CHEK2-*positive (green line) and *CHEK2-*negative patients (blue line) in (**A**) all patients, (**B**) patients not treated with adjuvant chemotherapy and (**C**) patients treated with adjuvant chemotherapy, and breast cancer-specific survival for *CHEK2-*positive (green line) and *CHEK2-*negative patients (blue line) in (**D**) all patients, (**E**) patients not treated with adjuvant chemotherapy and (**F**) patients treated with adjuvant chemotherapy.** \*In (**B**, **C**, **E** and **F**) stratified for adjuvant chemotherapy, an additional 7 carriers and 54 noncarriers for whom treatment with adjuvant chemotherapy was unknown were excluded.](bjc2014306f2){#fig2}

###### The *CHEK2* 1100delC status in the three different breast cancer patient cohorts

                                                     **Carriers**   **Noncarriers**          
  ------------------------------------------- ------ -------------- ----------------- ------ ------
  **Non-*BRCA1/2* familial**                                                                 
  All                                         1220   77             6.3               1143   93.7
  \<40                                        409    23             5.6               386    94.4
  40--50                                      474    26             5.5               448    94.5
  ⩾50                                         337    28             8.3               309    91.7
  **ORIGO (unselected for family history)**                                                  
  All                                         1014   29             2.9               985    97.1
  \<40                                        106    3              2.8               103    97.2
  40--50                                      283    11             3.9               272    96.1
  ⩾50                                         625    15             2.4               610    97.6
  **RMOT (unselected for family history)**                                                   
  All                                         2488   87             3.5               2401   96.5
  \<40                                        236    11             4.7               225    95.3
  40--50                                      628    22             3.5               606    96.1
  ⩾50                                         1624   54             3.3               1570   96.7
  Total                                       4722   193            4.1               4529   95.9

Abbreviations: *CHEK2*=*cell cycle checkpoint kinase 2*; RMOT=Rotterdam Medical Oncology Tumour bank.

###### Patient and tumour characteristics of *cell cycle checkpoint kinase 2* (*CHEK2*) 1100delC mutation carriers and noncarriers

                                                **Carrier**       **Noncarrier**                              
  --------------------------------------------- ----------------- ---------------- ----------------- -------- ---------
  Number of patients                            193                                4529                        
  Median follow-up in years                     6.8 (0.6--31.9)                    7.2 (0.1--38.9)             
  **Age at breast cancer diagnosis**                                                                          
  Median (years)                                50.0                               51.4                       0.003
  Mean (years)                                  50.1                               52.8                        
  Range (years)                                 22.5--78.0                         18.7--79.9                  
  \<40                                          37                19.2             714               15.8     0.14
  40--50                                        59                30.6             1326              29.3      
  ⩾50                                           97                50.3             2489              55.0      
  **Year of diagnosis**                                                                                       
  \<1990                                        58                30.1             1590              35.1     0.04
  1990--2000                                    83                43.0             1996              44.1      
  \>2000                                        52                26.9             943               20.8      
  **Synchronous contralateral breast cancer**                                                                 
  No                                            189               97.9             4443              98.1     0.87
  Yes                                           4                 2.1              86                1.9       
  **T stage**                                                                                                 
  T1                                            95                51.9             2074              47.2     0.23
  T2                                            72                39.3             1886              42.9      
  T3                                            11                6.0              264               6.0       
  T4                                            5                 2.7              168               3.8       
  Unknown                                       10                (5.2)            137               (3.0)     
  **N stage**                                                                                                 
  Negative                                      105               57.1             2388              53.9     0.31
  1--3                                          35                19.0             1096              24.7      
  4+                                            44                23.9             949               21.4      
  Unknown                                       9                 (4.7)            96                (2.1)     
  **Differentiation grade**                                                                                   
  1                                             21                14.7             370               10.5     0.11
  2                                             52                36.4             1155              32.6      
  3                                             70                49.0             2014              56.9      
  Unknown                                       50                (25.9)           990               (21.9)    
  **Hormone receptor status**                                                                                 
  Negative                                      9                 5.5              759               19.3     \<0.001
  Positive                                      157               94.5             3173              80.7      
  Unknown                                       30                (15.5)           597               (13.2)    
  **HER2/neu**                                                                                                
  Negative                                      73                76.0             1886              80.7     0.26
  Positive                                      23                24.0             452               19.3      
  Unknown                                       97                (50.2)           2191              (48.3)    

###### Types of treatment in *CHEK2* 1100delC mutation carriers and noncarriers

                                             **Carrier**   **Noncarrier**                                           
  ------------------------------------------ ------------- ---------------- -------------------------------- ------ -------
  **Surgical therapy**                                                                                              
  None                                       0             0                10                               0.2    0.80
  Lumpectomy                                 88            47.1             2087                             46.4    
  Mastectomy                                 99            52.9             2405                             53.4    
  Unknown                                    6                              27                                       
  **Adjuvant systemic therapy**                                                                                     
  None                                       117           63.2             2646                             59.3   0.42
  Only chemotherapy                          32            17.3             826                              18.5    
  Only hormonal therapy                      12            6.5              441                              9.9     
  Chemo- and hormonal therapy                24            13.0             547                              12.3    
  Unknown                                    8                              69                                       
  **(Neo)-adjuvant chemotherapy**                                                                                   
  None                                       129           69.4             3089                             69.0   0.41
  Anthracyclines                             38            20.4             838                              18.7    
  Anthracyclines/taxanes                     0             0                68                               1.5     
  Other                                      16            8.6              435[a](#t3-fn2){ref-type="fn"}   9.7     
  Unknown type                               3             1.6              45                               1.0     
  Unknown if treated                         7                              54                                       
  **Adjuvant hormonal therapy**                                                                                     
  None                                       143           77.3             3392                             76.0   0.46
  LHRH/ other                                6             3.2              84[b](#t3-fn3){ref-type="fn"}    1.9     
  Tamoxifen                                  33            17.8             812                              18.2    
  Aromatase inhibitor                        1             0.5              29                               0.6     
  Sequential tamoxifen/aromatase inhibitor   2             1.1              120                              2.7     
  Unknown type                               0             0                27                               0.6     
  Unknown if treated                         8                              65                                       
  **Radiotherapy**                                                                                                  
  No                                         73            38.0             1298                             28.7   0.006
  Yes                                        119           62.0             3220                             71.3    
  Unknown                                    1                              11                                       

Abbreviations: *CHEK2*=*cell cycle checkpoint kinase 2*; LHRH=luteinising-hormone-releasing hormone.

Four patients received taxanes.

Four patients were treated with radiotherapy of the ovaries or oophorectomy.

###### Rate of metachronous contralateral breast cancer[a](#t4-fn2){ref-type="fn"}

                                 **Carrier**         **Noncarrier**              **HR univariate**    **HR multivariate**
  ------------------------------ ------------------- ----------------- --------- -------------------- -----------------------------------------------
  **All patients**                                                                                    
  5 Years                        18.3 (11.7--28.0)   3.8 (3.1--4.5)    \<0.001   4.07 (2.66--6.21)    3.97 (2.59--6.07)[b](#t4-fn3){ref-type="fn"}
  10 Years                       28.9 (19.1--42.1)   8.5 (7.2--9.7)                                    
  **No adjuvant chemotherapy**                                                                        
  5 Years                        17.7 (10.3--29.3)   4.2 (2.3--5.0)    \<0.001   3.18 (1.87--5.40)    3.15 (1.86--5.35)[b](#t4-fn3){ref-type="fn"}
  10 Years                       24.1 (14.1--39.2)   8.8 (7.3--10.2)                                   
  **Adjuvant chemotherapy**                                                                           
  5 Years                        21.9 (9.1--42.2)    2.8 (1.7--4.2)    \<0.001   7.35 (3.42--15.08)   6.95 (3.21--15.00)[b](#t4-fn3){ref-type="fn"}
  10 Years                       42.1 (22.6--77.4)   7.4 (5.3--10.6)                                   

Abbreviations: *CHEK2*=*cell cycle checkpoint kinase 2*; CI=confidence interval; HR=hazard ratio.

For analyses regarding contralateral breast cancer (CBC), the non-BRCA1/2 cohort was excluded, because this cohort was probably enriched with patients with CBC.

Adjusted for year of diagnosis, cohort and type of surgery. Other covariates, that is, age at diagnosis, tumour size, nodal status, hormone receptor status, differentiation grade, type of surgery, type of chemotherapy, hormonal therapy and radiotherapy, had an impact of \<10% on the HR.

###### Distant disease-free and breast cancer-specific survival

                                        **HR \<6 years after diagnosis**   **HR ⩾6 years after diagnosis**                                    
  ------------------------------------- ---------------------------------- ---------------------------------------------- ------------------- -----------------------------------------------
  **Distant disease-free survival**                                                                                                           
  All patients                          1.02 (0.78--1.33)                  1.08 (0.83--1.42)[a](#t5-fn2){ref-type="fn"}   2.15 (1.45--3.18)   2.65 (1.79--3.93)[a](#t5-fn2){ref-type="fn"}
  No adjuvant chemotherapy              0.90 (0.64--1.27)                  0.98 (0.69--1.38)[b](#t5-fn3){ref-type="fn"}   1.98 (1.19--3.28)   2.31 (1.39--3.83)[b](#t5-fn3){ref-type="fn"}
  Adjuvant chemotherapy                 1.38 (0.90--2.13)                  1.41 (0.91--2.16)[c](#t5-fn4){ref-type="fn"}   3.64 (1.94--6.81)   4.54 (2.41--8.56)[c](#t5-fn4){ref-type="fn"}
  Anthracycline-based chemotherapy      1.58 (0.92--2.72)                  1.59 (0.92--2.75)[c](#t5-fn4){ref-type="fn"}   3.64 (1.55--8.55)   4.16 (1.69--10.22)[c](#t5-fn4){ref-type="fn"}
  Nonanthracycline-based chemotherapy   1.23 (0.61--2.50)                  1.16 (0.57--2.35)[c](#t5-fn4){ref-type="fn"}   3.76 (1.49--9.47)   4.73 (1.85--12.09)[c](#t5-fn4){ref-type="fn"}
  No adjuvant hormonal therapy          1.01 (0.75--1.36)                  1.08 (0.80--1.45)[a](#t5-fn2){ref-type="fn"}   2.43 (1.59--3.71)   2.88 (1.88--4.41)[a](#t5-fn2){ref-type="fn"}
  Adjuvant hormonal therapy             1.22 (0.66--2.23)                  1.36 (0.74--2.51)[a](#t5-fn2){ref-type="fn"}   2.79 (1.01--7.73)   3.24 (1.16--9.03)[a](#t5-fn2){ref-type="fn"}
  **Breast cancer-specific survival**                                                                                                         
  All patients                          0.96 (0.68--1.35)                  1.00 (0.71--1.41)[b](#t5-fn3){ref-type="fn"}   1.75 (1.20--2.54)   2.05 (1.41--2.99)[b](#t5-fn3){ref-type="fn"}
  No adjuvant chemotherapy              0.92 (0.60--1.41)                  1.00 (0.65--1.53)[b](#t5-fn3){ref-type="fn"}   1.68 (1.03--2.73)   2.03 (1.25--3.32)[b](#t5-fn3){ref-type="fn"}
  Adjuvant chemotherapy                 1.10 (0.61--1.97)                  1.05 (0.59--1.88)[b](#t5-fn3){ref-type="fn"}   2.33 (1.29--4.21)   2.55 (1.40--4.64)[b](#t5-fn3){ref-type="fn"}

Abbreviations: CI=confidence interval; HR=hazard ratio.

Adjusted for tumour size and chemotherapy, and other covariates had an impact of \<10% on the HR.

Adjusted for tumour size, and other covariates had an impact of \<10% on the HR.

Adjusted for tumour size and hormonal therapy, and other covariates had an impact of \<10% on the HR.

###### Prognostic factors for breast cancer-specific survival, separately for the *CHEK2* and non-*CHEK2* group

                                  **Carrier**         **Noncarrier**
  ------------------------------- ------------------- --------------------
  **Age at diagnosis**                                
  Per year older                  0.99 (0.97--1.01)   0.99 (0.99--0.996)
  **Tumour size**                                     
  T1                              1                   1
  T2, 3 and 4                     4.29 (2.34--7.87)   2.46 (1.98--3.06)
  Tumour size × time (in years)                       0.95 (0.92--0.98)
  **Nodal status**                                    
  Negative                        1                   1
  Positive                        2.28 (1.17--4.46)   2.72 (2.36--3.15)
  **ER status**                                       
  Negative                        1                   1
  Positive                        1.11 (0.43--2.84)   0.58 (0.45--0.75)
  **Chemotherapy**                                    
  No                              1                   1
  Yes                             0.70 (0.35--1.41)   0.68 (0.58--0.80)
  **Hormonal therapy**                                
  No                              1                   1
  Yes                             0.62 (0.30--1.28)   0.89 (0.76--1.05)

Abbreviations: *CHEK2*=*cell cycle checkpoint kinase 2*; CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio.
